Eptinezumab (Vyepti) vs Fremanezumab (Ajovy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: CGRP ligand · full Migraine pipeline
Eptinezumab (Vyepti)
Marketed by H. Lundbeck
NCT02974153 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 1,121 participants. The hard clinical primary endpoint was met for both doses: monthly migraine days decreased by 8.2 days with 300 mg and 7.7 days with 100 mg versus 5.6 days with placebo, with both comparisons statistically significant (p<0.0001).
Next expected readout: March 2027 · NCT04965675 (registry estimate)
Reported efficacy
Change From Baseline in Monthly Migraine Days (Week 1-12): Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9) (met)
Result source: NCT02974153
Fremanezumab (Ajovy)
Marketed by Teva Pharmaceutical Industries and partners
NCT02638103 · Phase 3 · completed
This was a large, quadruple-masked rollover/extension study continuing participants from two prior fremanezumab randomized trials, with placebo-matched injections used to preserve masking across monthly and quarterly regimens. Its primary outcomes were descriptive safety measures, and the study did not report a formal placebo-controlled primary efficacy comparison, so it provides useful but limited evidence for fremanezumab.
Reported efficacy
Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug (Baseline (Day -28 to Day -1), up to Week 12): Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results). (met)
Result source: NCT04458857
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eptinezumab (Vyepti)'s landscape · Fremanezumab (Ajovy)'s landscape